View in EDS

VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN.

Saved in:
Bibliographic Details
Title: VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN.
Authors: Nester, Carla M.1 (AUTHOR), Bomback, Andrew S.2 (AUTHOR), Ariceta, Gema3 (AUTHOR), Delmas, Yahsou4 (AUTHOR), Dixon, Bradley P.5 (AUTHOR), Gale, Daniel P.6 (AUTHOR), Greenbaum, Larry A.7 (AUTHOR), Han, Seung Hyeok8 (AUTHOR), Isbel, Nicole9,10 (AUTHOR), Licht, Christoph11 (AUTHOR), Mastrangelo, Antonio12 (AUTHOR), Mizuno, Masashi13 (AUTHOR), de Holanda, Maria Izabel Neves14 (AUTHOR), Pickering, Matthew C.15 (AUTHOR), Remuzzi, Giuseppe16 (AUTHOR), Van De Kar, Nicole17 (AUTHOR), Vivarelli, Marina18 (AUTHOR), Walker, Patrick D.19 (AUTHOR), Wallace, Dean20 (AUTHOR), Zecher, Daniel21 (AUTHOR)
Source: Immunobiology. Jul2025, Vol. 230 Issue 4, pN.PAG-N.PAG. 1p.
Database: Academic Search Ultimate
Description
ISSN:01712985
DOI:10.1016/j.imbio.2025.153039